Company Update

Securities and Exchange Commission under Rule 497 of the Securities Act on May 23, 2023, and the Prospectus Supplement is incorporated by reference herein.   The offering documents cited next generation technology development as a potential use of proceeds, among other potential uses. In this regard, the Company hereby announces that it has reserved $1,900,000 of the net proceeds from the May 22, 2023 public offering to support the continued development of its next generation optical blood volume analyzer systems.   The Company anticipates that development work will proceed over a 24 month period, and expects it will be done in conjunction with other technology development efforts supported by the Department of Defense. The Company is excited to be moving forward its next generation technologies.         SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.     DAXOR CORPORATION   (Registrant)     Date: October 27, 2023 By: /s/ Robert J. Michel   Name: Robert J. Michel   Title: Chief Financial Officer